<DOC>
	<DOCNO>NCT00816816</DOCNO>
	<brief_summary>The primary objective study determine tolerance overall survival patient stage ⅣAB NPC treat neoadjuvant chemotherapy concurrent chemoradiation . Secondary objective study evaluate distant metastasis free survival , disease-free survival patient stage ⅣAB treat regimen</brief_summary>
	<brief_title>Phase Ⅱ Study Neoadjuvant Chemotherapy Followed Concurrent Chemoradiation Stage ⅣAB Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Concurrent chemoradiation standard treatment locally advance NPC . The survival benefit gain add neoadjuvant chemotherapy concurrent chemoradiation never define . In present trail , hope assess tolerance survival benefit neoadjuvant chemotherapy follow concurrent chemoradiation patient stage ⅣAB NPC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically proven differentiate nonkeratinizing carcinoma , undifferentiated carcinoma nasopharynx . Stage ⅣAB disease KPS &gt; 70 Age 1870 Patients adequate bone marrow function define absolute peripheral granulocyte count ( AGC ) &gt; 2000 cells/mm3 , platelet count &gt; 100,000 cells/mm3 ( pre treatment without intervention ) . Bilirubin &lt; 1.5 mg/dl , AST ALT &lt; 2 x upper normal , serum creatinine &lt; 1.5mg/dl , creatinine clearance &gt; 50ml/min . No prior radiation treatment head neck prior chemotherapy Patients prior malignancy ( include basal cell carcinoma skin ) Evidence metastasis ( clavicle distant ) clinical radiographic examination . Prior radiotherapy head neck region reason . Initial surgical treatment exclude diagnostic biopsy primary site neck disease . Patients previous simultaneous primary , exclude basal cell carcinoma squamous cell carcinoma skin . Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Phase 2 Clinical Trial</keyword>
	<keyword>NPC</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>concurrent chemoradiation</keyword>
</DOC>